Floatz logo

Ocrelizumab

Multiple Sclerosis

Polpharma Biologics International AGmonoclonal_antibodyPhase 4 / ApprovedActive
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
76/ 100
Competitive Position
65/ 100

Competitive context

181 Active assets in the Multiple Sclerosis cohort.

Asset / SponsorPhaseRating
Cladribine
University Hospital, Strasbourg, France
Phase 4BBB
Fampridine
MGH Institute of Health Professions
Phase 4BBB
Nabiximols
Jazz Pharmaceuticals
Phase 4BBB
Teriflunomide
Sanofi
Phase 4BBB
Methylphenidate
Johns Hopkins University
Phase 3BB

View all 50 →

Same molecule, other indications

Ocrelizumab is also rated in:

relapsing-remitting multiple sclerosisActive
BBB
Indicative · Phase 4
76 / 100
View asset →
primary progressive multiple sclerosisActive
BBB
Indicative · Phase 4
76 / 100
View asset →
secondary progressive multiple sclerosisActive
BB
Indicative · Phase 3
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →